Rather, our aim is to allow a level of flexibility in the components to resolve the tension between the need for optimisation and variability – what the market wants, or clients need.

We use this input to create a comprehensive and holistic model of the problem and the outline solution.We call this process Chip Thinking®️.

It allows us to generate outputs about its performance under different conditions..This is a powerful picture that allows all stakeholders to understand the problem and come up with creative ideas in a structured way that take into account what others know, while focusing on aspects that matter to achieve a successful solution.Jointly they can then decide what to do next.

Do we need better data or knowledge about a certain aspect?Do we need to model some aspects in more detail?

Does the solution need to be completely different?

Have we formulated the problem properly in the first place?A significant focus is on the concept of miniaturisation and continuous processing as part of a new paradigm in drug manufacturing.

This approach not only reduces the environmental footprint and costs but also enhances safety and quality by enabling smaller, more controlled, and flexible production processes.. 5.Barriers and opportunities for change:.

Finally, Adrian discusses the systemic and regulatory barriers to adopting these new manufacturing technologies but also highlights the compelling need for change driven by the demand for affordable, sustainable medicines.He advocates for embracing these new technologies to overcome current limitations and transform pharmaceutical manufacturing..